Back
 JBM  Vol.6 No.12 , December 2018
Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System
Abstract: Objectives: The cost-utility analysis of Liraglutide is aimed at evaluating whether Liraglutide is cost-effective or not after Chinese reformation on medical insurance. The analysis is based on the results of clinical trial conducted in Asia. Methods: We applied a Markov model to estimate the quality-adjusted life years, medical cost and incidence of diabetes-related complications for patients receiving the Liraglutide as an add-on to the metformin treatment. Baseline characteristics were taken from a China’s study while the treatment effect is from an Asian study. The related medical cost and utility score were obtained from a local study in China. Having set 30 years’ simulations, the incremental cost-effectiveness ratio was calculated comparing with glimepiride treatment. The ratio would be compared with the willingness to pay for a quality-adjusted-life-year (QALY) which is three times of the GDP per capita in Beijing. Sensitivity analysis was also performed. Result: During a period of 30 years, the base-case analysis which takes discount rate at 3% shows that Liraglutide 1.8 mg results in an average incremental cost of CNY 82,671.49, an improvement in 0.12 QALYs and a reduction of incidence of diabetes-related complications comparing to glimepiride. The associated incremental cost-effectiveness ratio is CNY 688,929.08. Conclusion: Long-term project shows that taking Liraglutide as an add-on to the metformin treatment will lead to increasing quality-adjusted life years and reduction of incidence of diabetes-related complications. When the price of Liraglutide is reduced by 43 percent in China’s yuan, Liraglutide will be cost-effective in China from the healthcare system perspective taking three times of GDP per capita as our WTP threshold.
Cite this paper: Xie, G. and Zhao, S. (2018) Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System. Journal of Biosciences and Medicines, 6, 13-25. doi: 10.4236/jbm.2018.612002.
References

[1]   Yang, L., Shao, J., Bian, Y., Wu, H., Shi, L., Zeng, L., et al. (2016) Prevalence of Type 2 Diabetes Mellitus among Inland Residents in China (2000-2014): A Meta-Analysis. Journal of Diabetes Investigation, 7, 845-852.
https://doi.org/10.1111/jdi.12514

[2]   Wang, W., Mcgreevey, W.P., Fu, C., Zhan, S., Luan, R., Chen, W., et al. (2009) Type 2 Diabetes Mellitus in China: A Preventable Economic Burden. American Journal of Managed Care, 15, 593-601.

[3]   Ministry of Human Resources and Social Security of the People’s Republic of China. (2017) Notice of the Ministry of Human Resources and Social Security on the Inclusion of 36 Drugs in the Category B of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List.
http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718
_274153.html


[4]   Perry, C.M. (2011) Liraglutide: A Review of its use in the Management of Type 2 Diabetes Mellitus. Drugs, 71, 2347-2373.
https://doi.org/10.2165/11208110-000000000-00000

[5]   DTB (2017) Liraglutide for Weight Management. BMJ, 55, 78-81.

[6]   Takeyuki, H., Yuko, A., Masatsuna, M., Imai, K., Iguchi, D. and Furuta, S. (2018) Liraglutide Relieves Cardiac Dilated Function than DPP-4 Inhibitors. European Journal of Clinical Investigation, 48, e13007.
https://doi.org/10.1111/eci.13007

[7]   Camkurt, M.A., Lavagnino, L., Zhang, X.Y. and Teixeira, A.L. (2018) Liraglutide for Psychiatric Disorders: Clinical Evidence and Challenges. Hormone Molecular Biology & Clinical Investigation. Published Online.

[8]   Novo Nordisk, A.S. (2018) Effect of Liraglutide or Glimepiride Added to Metformin on Blood Control in Subject with Type 2 Diabetes.
https://www.clinicaltrials.gov/ct2/show/NCT00614120?recrs=e&rslt=With&cond=liraglutide&
cntry=CN&rank=1


[9]   Briggs, A. and Sculpher, M. (1998) An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 13, 397-409.
https://doi.org/10.2165/00019053-199813040-00003

[10]   Xie, X. and Vondeling, H. (2010) Cost-Utility Analysis of Intensive Blood Glucose Control with Metformin versus Usual Care in Overweight Type 2 Diabetes Mellitus Patients in Beijing, P.R. China. Value in Health, 11, S23-S32.
https://doi.org/10.1111/j.1524-4733.2008.00363.x

[11]   Li, X., Xu, Z., Ji, L., Guo, L., Feng, K., Xu, Y., et al. (2018) Direct Medical Costs for Patients with Type 2 Diabetes in 16 Tertiary Hospitals in Urban China: A Multicenter Prospective Cohort Study. Journal of Diabetes Investigation, 2040-1116.
https://doi.org/10.1111/jdi.12905

[12]   Listed, N. (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 854.
https://doi.org/10.1016/S0140-6736(98)07037-8

[13]   Jr, C.C. (1998) The Burden of Chronic Hyperglycemia. Diabetes Care, 21, C32-C34.
https://doi.org/10.2337/diacare.21.3.C32

[14]   Beijing Pharmaceutical Centralized Purchasing Service Center (2018) Integrated Management Platform of Beijing Medicine Sunshine Purchase.

[15]   Luo, Y.J., Fang, Y. and Ding, X.S. (2009) The Quality of Life of Patients with Rype 2 Diabetes Measured by EQ-5D and Its Influential Factors Analysis. China Journal of Pharmaceutical Economics, No. 2, 12-18.

[16]   Commission on Macroeconomics and Health of WHO (2018) Investing in Health: A Summary of the Findings of the Commission on Macroeconomics and Health.
http://www.who.int/macrohealth/infocentre/advocacy/en/investinginhealth02052003.pdf?ua=1

[17]   Zhao, F.L., Yue, M., Yang, H., Wang, T., Wu, J.H. and Li, S.C. (2011) Willingness to Pay per Quality-Adjusted Life Year: Is One Threshold Enough for Decision-Making? Results from a Study in Patients with Chronic Prostatitis. Medical Care, 49, 267-272.
https://doi.org/10.1097/MLR.0b013e31820192cd

[18]   Eastman, R.C., Javitt, J.C., Herman, W.H., Dasbach, E.J., Zbrozek, A.S., Dong, F., et al. (1997) Model of Complications of NIDDM: I. Model Construction and Assumptions. Diabetes Care, 20, 725-734.
https://doi.org/10.2337/diacare.20.5.725

[19]   Eastman, R.C., Javitt, J.C., Herman, W.H., Dasbach, E.J., Copley-Merriman, C., Maier, W., et al. (1997) Model of Complications of NIDDM. II. Analysis of the Health Benefits and Cost-Effectiveness of Treating NIDDM with the Goal of Normoglycemia. Diabetes Care, 20, 735-744.
https://doi.org/10.2337/diacare.20.5.725

[20]   Group, C.E.S. (1998) The Cost-Effectiveness of Screening for Type 2 Diabetes. JAMA, 280, 1757-1763.
https://doi.org/10.1001/jama.280.20.1757

[21]   Petitti, D. (2000) Meta-Analysis Decision Analysis and Cost-Effectiveness Analysis. 2nd Edition, Oxford University Press, New York, 141-168.

[22]   Gao, L., Zhao, F.L. and Li, S.C. (2012) Cost-Utility Analysis of Liraglutide versus Glimepiride as Add-On to Metformin in Type 2 Diabetes Patients in China. International Journal of Technology Assessment in Health Care, 28, 436-444.
https://doi.org/10.1017/S0266462312000608

[23]   Clarke, P., Gray, A. and Holman, R. (2002) Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62). Medical Decision Making, 22, 340-349.
https://doi.org/10.1177/027298902400448902

[24]   Clarke, P.M., Gray, A.M., Briggs, A., Farmer, A.J., Fenn, P., Stevens, R.J., et al. (2004) A Model to Estimate the Lifetime Health Outcomes of Patients with Type 2 Diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS No. 68). Diabetologia, 47, 1747-1759.
https://doi.org/10.1007/s00125-004-1527-z

[25]   Novo Nordisk (2018) Novo Nordisk Annual Report 2017.
https://www.novonordisk.com/annualreport

[26]   Novo Nordisk (2018) Novo Nordisk’s Operating Profit Decreased by 8% in Danish Kroner and Increased by 6% in Local Currencies in the First Three Months of 2018.
https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/
media/news-details.2189261.html


 
 
Top